CRIS Current Research Information System

DI STEFANO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.556
NA - Nord America 4.091
EU - Europa 3.024
AF - Africa 259
SA - Sud America 229
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.028
VN - Vietnam 1.290
CN - Cina 1.239
SG - Singapore 1.115
IT - Italia 844
GB - Regno Unito 564
DE - Germania 286
HK - Hong Kong 248
SE - Svezia 229
IN - India 206
FR - Francia 180
BR - Brasile 174
UA - Ucraina 144
KR - Corea 140
CH - Svizzera 125
RU - Federazione Russa 125
IE - Irlanda 119
FI - Finlandia 88
JP - Giappone 87
TG - Togo 85
NL - Olanda 82
CI - Costa d'Avorio 60
ZA - Sudafrica 46
BG - Bulgaria 44
EE - Estonia 36
CA - Canada 32
PH - Filippine 32
AT - Austria 30
JO - Giordania 29
NG - Nigeria 26
TW - Taiwan 26
MX - Messico 24
AR - Argentina 23
ES - Italia 23
BE - Belgio 22
TR - Turchia 22
ID - Indonesia 21
IQ - Iraq 20
PL - Polonia 20
SC - Seychelles 20
TH - Thailandia 19
DK - Danimarca 15
BD - Bangladesh 13
GR - Grecia 10
HR - Croazia 10
SA - Arabia Saudita 10
AU - Australia 9
MA - Marocco 9
EC - Ecuador 7
IR - Iran 7
LT - Lituania 6
PK - Pakistan 6
PY - Paraguay 6
CO - Colombia 5
RO - Romania 5
VE - Venezuela 5
CL - Cile 4
LB - Libano 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
IL - Israele 3
MD - Moldavia 3
NP - Nepal 3
PE - Perù 3
PT - Portogallo 3
UZ - Uzbekistan 3
CZ - Repubblica Ceca 2
ET - Etiopia 2
KE - Kenya 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
RS - Serbia 2
SI - Slovenia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BH - Bahrain 1
BT - Bhutan 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GT - Guatemala 1
HU - Ungheria 1
JM - Giamaica 1
LY - Libia 1
ME - Montenegro 1
MM - Myanmar 1
MT - Malta 1
MU - Mauritius 1
MW - Malawi 1
NC - Nuova Caledonia 1
PA - Panama 1
PR - Porto Rico 1
SM - San Marino 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 12.171
Salva come PNG Salva come JPEG
Città #
Singapore 808
Ashburn 543
Southend 442
Fairfield 374
Chandler 323
Hefei 298
Ho Chi Minh City 296
Bologna 285
Hanoi 270
Hong Kong 225
Santa Clara 206
Woodbridge 202
San Jose 196
Wilmington 169
Houston 163
Seattle 162
Beijing 130
Ann Arbor 122
Dublin 117
Bern 116
Seoul 113
Cambridge 103
Princeton 100
Dong Ket 94
Jacksonville 87
Lomé 85
Boardman 82
Helsinki 70
Tokyo 69
New York 68
Dallas 66
Lauterbourg 66
Abidjan 60
Los Angeles 58
Milan 57
Nanjing 49
Redmond 46
Da Nang 43
Sofia 43
Westminster 41
Haiphong 40
Padova 39
Bengaluru 37
Buffalo 32
Berlin 31
Shenyang 30
Council Bluffs 28
Frankfurt am Main 28
Guangzhou 28
Turin 28
Amman 27
Genoa 26
Abeokuta 24
Jinan 24
Shanghai 24
Amsterdam 22
San Diego 22
Tianjin 21
Falkenstein 20
São Paulo 20
Brussels 19
Changsha 19
Hangzhou 19
Redondo Beach 19
Saint Petersburg 19
Quận Bình Thạnh 18
Rome 18
Thái Nguyên 18
Düsseldorf 17
London 17
Vienna 17
Nanchang 16
Warsaw 16
Mülheim 15
Baghdad 14
Can Tho 14
Nuremberg 14
Biên Hòa 13
Chennai 13
Chicago 13
Falls Church 13
Florence 13
Jakarta 13
Mahé 13
Montreal 13
Redwood City 13
Wanchai 13
Zhengzhou 13
Copenhagen 12
Hải Dương 12
Munich 12
Ninh Bình 12
Paris 12
Salt Lake City 12
The Dalles 12
Verona 12
Yubileyny 12
Cesenatico 11
Hebei 11
Phoenix 11
Totale 7.971
Salva come PNG Salva come JPEG
Nome #
A RAD51/BRCA2 small molecule inhibitor enhances the antineoplastic effect of the PARPi talazoparib in pancreatic cancer 346
Lactate-Induced HBEGF Shedding and EGFR Activation: Paving the Way to a New Anticancer Therapeutic Opportunity 306
Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells 275
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib 270
Insights into the activity of ARN24089, a new RAD51-BRCA2 disruptor that inhibits homologous recombination and achieves synthetic lethality in pancreatic cancer 250
Lactate preserves genome integrity and extends proliferative potential in cancer cells 246
A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. 239
Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy. 232
Altered glycosylation profile of purified plasma ACT from Alzheimer's disease. 229
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity 224
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. 222
Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells 218
Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. 216
Liver targeted doxorubicin: effects on rat regenerating hepatocytes. 215
The activation of lactate dehydrogenase induced by mTOR drives neoplastic change in breast epithelial cells 215
LDH inhibition impacts on heat shock response and induces senescence of hepatocellular carcinoma cells 212
Lactate dehydrogenase inhibition affects homologous recombination repair independently of cell metabolic asset; implications for anticancer treatment 210
Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. 209
Lactate is a potential promoter of tamoxifen resistance in MCF7 cells 207
Identification and subsequent development of RAD51-BRCA2 disruptors through a fragment-based approach 205
Uso di coniugati della doxorubicina con albumina lattosaminata 200
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer 199
Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes. 199
Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines. 197
Galloflavin (CAS 568-80-9), a novel inhibitor of lactate dehydrogenase. 195
Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin 194
Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors 193
A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentation grade. 193
Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. 192
Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. 191
Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties. 189
Preomic profile of BxPC-3 cells after treatment with BRC4 188
Differential enantiomers activity of ARN24089 to achieve synthetic lethality in pancreatic cancer 187
Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A 187
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. 182
Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulationin Burkitt lymphoma cells via NAD/NADH-dependent inhibition of sirtuin-1 181
Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. 179
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug. 178
Metabolic activation triggered by cAMP in MCF-7 cells generates lethal vulnerability to combined oxamate/etomoxir 174
Doxorubicin coupled to lactosaminated albumin: effects on rats with liver fibrosis and cirrhosis. 170
The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination 167
Albumin-drug conjugates in the treatment of hepatic disorders. 167
Peptides inhibiting the assembly of monomeric human l‐lactate dehydrogenase into catalytically active homotetramer decrease the synthesis of lactate in cultured cells 166
The enhancement of interstitial transport of a doxorubicin-lactosaminated albumin conjugate by imatinib: in rat hepatocellular carcinoma it is not preferentially higher than that in liver and bone marrow. 165
Procedura per la preparazione di coniugati della doxorubicina con l’albumina umana lattosaminata 163
Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. 163
Allosteric transitions of rabbit skeletal muscle lactate dehydrogenase induced by pH-dependent dissociation of the tetrameric enzyme 160
Lactate Can Modulate the Antineoplastic Effects of Doxorubicin and Relieve the Drug's Oxidative Damage on Cardiomyocytes 155
Lactate Upregulates the Expression of DNA Repair Genes, Causing Intrinsic Resistance of Cancer Cells to Cisplatin 152
Elevated plasma levels of alpha-1-antichymotripsin in age-related cognitive decline and Alzheimer's disease; a poential therapeutci target. 151
Process for the preparation of doxorubicin conjugates with lactosaminated human albumin 147
Doxorubicin coupled to lactosaminated albumin: enhanced drug levels in rat hepatocarcinomas. 143
Use of conjugates of doxorubicin with lactosaminated albumin. 138
Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors 133
NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases 131
Lactosaminated human albumin: a hepatotropic carrier of drugs. 129
Human lactate dehydrogenase A undergoes allosteric transitions under pH conditions inducing the dissociation of the tetrameric enzyme 129
Proteomic profile of BxPC-3 cells after treatment with BRC4 117
Lactate dehydrogenase inhibition: Exploring possible applications beyond cancer treatment 116
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy 111
Inhibition of lactate dehydrogenase activity as an approach to cancer therapy 107
null 101
RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer 86
null 78
null 71
Increased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues 67
Expression of UDP-GalNAc:NeuAc alpha 2,3Gal beta-R beta 1,4(GalNAc to Gal) N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas 63
Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series 62
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in cancer treatment 61
Design and synthesis of RAD51-BRCA2 disruptors to inhibit homologous recombination and synergize with Olaparib as new anticancer drug discovery concept 55
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy 54
Postnatal development of rat colon epithelial cells is associated with changes in the expression of the beta 1,4-N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen of alpha 2,6-sialyltransferase activity towards N-acetyl-lactosamine 52
null 51
A Metabolites' Interplay Can Modulate DNA Repair by Homologous Recombination 45
Totale 12.370
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.428
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.428
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021267 0 0 0 0 0 0 0 0 0 50 42 175
2021/2022986 110 19 76 84 74 45 42 73 39 66 190 168
2022/20231.365 111 219 50 154 115 89 40 51 207 38 71 220
2023/2024670 89 79 46 57 41 121 66 37 15 41 22 56
2024/20251.896 108 167 119 159 335 103 148 81 66 138 117 355
2025/20264.653 710 512 428 458 469 217 407 168 993 291 0 0
Totale 12.370